PsychoactiveMap

Psychedelic and ketamine research trials in Bulgaria

Curated snapshot as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap.

This is a dated selection from the broader clinical catalogue for Bulgaria, not a complete inventory of research. The catalogue loads separately, may show cached records, and includes compounds and ketamine uses outside this hub's scope. Scope and update timing can produce different totals. Historical publications are separate from these registered-study counts.

4 registered studies are counted in Bulgaria. By compound: 4 ketamine. By registry status: 4 completed. By phase: 1 phase 2, 2 phase 3 and 1 phase 4. Reported start years run from 2017 (earliest) to 2021 (latest). Studies are linked to 14 source-listed facility records.

Country is taken from the research sites linked to each registry record. A study counts once per country and may appear in several countries. Compound counts may overlap. This directory covers its linked compound hubs; the research map and MCP connector also include other compounds. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.

Facility records may include aliases or departments of the same institution; they are not a count of unique institutions. A listed facility does not establish a sponsor, lead site or care provider role, or confirm recruitment.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

Recruiting or not yet recruiting

None of the 4 counted studies in Bulgaria is listed in the registry as recruiting or not yet recruiting as of 31 October 2026. Status is reported by study teams and can be out of date.

At a glance

By compound

Compound hubStudies
Ketamine4

By registry status

StatusStudiesShare
Completed4100%

By phase

PhaseStudiesShare
Phase 2125%
Phase 3250%
Phase 4125%

Registry-listed start years

Start yearStudies
2020 to 20232
2015 to 20192

All counted studies

All 4 counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesSource-listed facility and city
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray TreatmentNCT04829318CompletedPhase 4Source start: 2021-04-26 (actual)
Source date details

Start: 2021-04-26 (precision: day; source type: ACTUAL; actual)

Primary completion: 2024-07-22 (precision: day; source type: ACTUAL; actual)

Study completion: 2024-07-22 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:15.827Z; registry revision: 2025-09-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Mental Health Center - Rousse, Rousse; Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum, Sofia; Centre for Mental Health Prof.N.Shipkovenski EOOD, Sofia
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderNCT04338321CompletedPhase 3Source start: 2020-08-21 (actual)
Source date details

Start: 2020-08-21 (precision: day; source type: ACTUAL; actual)

Primary completion: 2022-01-20 (precision: day; source type: ACTUAL; actual)

Study completion: 2022-07-15 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:12.343Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Mental Health Center - Plovdiv, Plovdiv; University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD, Sofia; Mental Health Center - Rousse, Rousse; State Psychiatric Hospital Kardzhali, Kardzhali; UMHAT 'Dr. Georgi Stranski', EAD, Pleven; Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum, Sofia; Centre for Mental Health Prof.N.Shipkovenski EOOD, Sofia; MHC - Sofia, EOOD, Sofia
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819CompletedPhase 2Source start: 2017-10-05 (actual)
Source date details

Start: 2017-10-05 (precision: day; source type: ACTUAL; actual)

Primary completion: 2023-03-31 (precision: day; source type: ACTUAL; actual)

Study completion: 2023-03-31 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:14.289Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Mental Health Center - Rousse, Rousse; Multiprofile Hospital for Active Treatment - MHAT Sveta Marina EAD, Varna
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192CompletedPhase 3Source start: 2017-06-09 (actual)
Source date details

Start: 2017-06-09 (precision: day; source type: ACTUAL; actual)

Primary completion: 2018-12-18 (precision: day; source type: ACTUAL; actual)

Study completion: 2018-12-18 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:14.289Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Regional Psychiatric Dispansery, Bulgaria; UMHAT 'Sveti Georgi'-Plovdiv, Plovdiv; State Psychiatric Hospital - Lovech, Lovech; Military Medical Academy Multiprofile Hospital for Active Treatment Sofia, Sofia; Mental Health Center Prof. Dr. Ivan Temkov, Burgas

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Ketamine

Source-facility hubs in this country

Source-listed facility records in this country with at least 3 counted studies. Each hub counts studies linked to its source record, which can include studies not shown above if the registry lists them under another country. Names may include aliases or departments.

Condition hubs

Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.

Other country hubs

United States | Canada | Switzerland | United Kingdom | Israel | Brazil | France | China | Netherlands | Germany | Spain | Austria | Australia | Poland | Czech Republic | Ireland | Denmark | Sweden | Taiwan | Argentina | Belgium | Finland | Turkey | Greece | Hungary | Italy | Mexico | Egypt | Norway | Pakistan | Portugal

All trial hubs | Learn | Disclaimer